213 related articles for article (PubMed ID: 26379078)
21. Prostate-specific membrane antigen in circulating tumor cells is a new poor prognostic marker for castration-resistant prostate cancer.
Nagaya N; Nagata M; Lu Y; Kanayama M; Hou Q; Hotta ZU; China T; Kitamura K; Matsushita K; Isotani S; Muto S; Sakamoto Y; Horie S
PLoS One; 2020; 15(1):e0226219. PubMed ID: 31986176
[TBL] [Abstract][Full Text] [Related]
22. Clinical implications of PTEN loss in prostate cancer.
Jamaspishvili T; Berman DM; Ross AE; Scher HI; De Marzo AM; Squire JA; Lotan TL
Nat Rev Urol; 2018 Apr; 15(4):222-234. PubMed ID: 29460925
[TBL] [Abstract][Full Text] [Related]
23. Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer.
Vogelzang NJ; Fizazi K; Burke JM; De Wit R; Bellmunt J; Hutson TE; Crane E; Berry WR; Doner K; Hainsworth JD; Wiechno PJ; Liu K; Waldman MF; Gandhi A; Barton D; Jungnelius U; Fandi A; Sternberg CN; Petrylak DP
Eur Urol; 2017 Feb; 71(2):168-171. PubMed ID: 27522164
[TBL] [Abstract][Full Text] [Related]
24. Circulating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancer.
Goodman OB; Symanowski JT; Loudyi A; Fink LM; Ward DC; Vogelzang NJ
Clin Genitourin Cancer; 2011 Sep; 9(1):31-8. PubMed ID: 21705286
[TBL] [Abstract][Full Text] [Related]
25. Longitudinal CTCs gene expression analysis on metastatic castration-resistant prostate cancer patients treated with docetaxel reveals new potential prognosis markers.
Pereira-Veiga T; González-Conde M; León-Mateos L; Piñeiro-Cid R; Abuín C; Muinelo-Romay L; Martínez-Fernández M; Brea Iglesias J; García González J; Anido U; Aguín-Losada S; Cebey V; Costa C; López-López R
Clin Exp Metastasis; 2021 Apr; 38(2):239-251. PubMed ID: 33635497
[TBL] [Abstract][Full Text] [Related]
26. A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer.
Armstrong AJ; Shen T; Halabi S; Kemeny G; Bitting RL; Kartcheske P; Embree E; Morris K; Winters C; Jaffe T; Fleming M; George DJ
Clin Genitourin Cancer; 2013 Dec; 11(4):397-406. PubMed ID: 23830964
[TBL] [Abstract][Full Text] [Related]
27. Integrated network model provides new insights into castration-resistant prostate cancer.
Hu Y; Gu Y; Wang H; Huang Y; Zou YM
Sci Rep; 2015 Nov; 5():17280. PubMed ID: 26603105
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.
Razis E; Bobos M; Kotoula V; Eleftheraki AG; Kalofonos HP; Pavlakis K; Papakostas P; Aravantinos G; Rigakos G; Efstratiou I; Petraki K; Bafaloukos D; Kostopoulos I; Pectasides D; Kalogeras KT; Skarlos D; Fountzilas G
Breast Cancer Res Treat; 2011 Jul; 128(2):447-56. PubMed ID: 21594665
[TBL] [Abstract][Full Text] [Related]
29. Circulating Tumor Cells as a Marker for Progression-free Survival in Metastatic Castration-naïve Prostate Cancer.
Josefsson A; Linder A; Flondell Site D; Canesin G; Stiehm A; Anand A; Bjartell A; Damber JE; Welén K
Prostate; 2017 Jun; 77(8):849-858. PubMed ID: 28295408
[TBL] [Abstract][Full Text] [Related]
30. Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience.
Olmos D; Arkenau HT; Ang JE; Ledaki I; Attard G; Carden CP; Reid AH; A'Hern R; Fong PC; Oomen NB; Molife R; Dearnaley D; Parker C; Terstappen LW; de Bono JS
Ann Oncol; 2009 Jan; 20(1):27-33. PubMed ID: 18695026
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of Pten deficient Castration Resistant Prostate Cancer by Targeting of the SET - PP2A Signaling axis.
Hu X; Garcia C; Fazli L; Gleave M; Vitek MP; Jansen M; Christensen D; Mulholland DJ
Sci Rep; 2015 Nov; 5():15182. PubMed ID: 26563471
[TBL] [Abstract][Full Text] [Related]
32. Combined MYC Activation and Pten Loss Are Sufficient to Create Genomic Instability and Lethal Metastatic Prostate Cancer.
Hubbard GK; Mutton LN; Khalili M; McMullin RP; Hicks JL; Bianchi-Frias D; Horn LA; Kulac I; Moubarek MS; Nelson PS; Yegnasubramanian S; De Marzo AM; Bieberich CJ
Cancer Res; 2016 Jan; 76(2):283-92. PubMed ID: 26554830
[TBL] [Abstract][Full Text] [Related]
33. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data.
Scher HI; Jia X; de Bono JS; Fleisher M; Pienta KJ; Raghavan D; Heller G
Lancet Oncol; 2009 Mar; 10(3):233-9. PubMed ID: 19213602
[TBL] [Abstract][Full Text] [Related]
34. Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial.
Autio KA; Dreicer R; Anderson J; Garcia JA; Alva A; Hart LL; Milowsky MI; Posadas EM; Ryan CJ; Graf RP; Dittamore R; Schreiber NA; Summa JM; Youssoufian H; Morris MJ; Scher HI
JAMA Oncol; 2018 Oct; 4(10):1344-1351. PubMed ID: 29978216
[TBL] [Abstract][Full Text] [Related]
35. Emerging Molecular Biomarkers in Advanced Prostate Cancer: Translation to the Clinic.
Beltran H; Antonarakis ES; Morris MJ; Attard G
Am Soc Clin Oncol Educ Book; 2016; 35():131-41. PubMed ID: 27249694
[TBL] [Abstract][Full Text] [Related]
36. The Novel Association of Circulating Tumor Cells and Circulating Megakaryocytes with Prostate Cancer Prognosis.
Xu L; Mao X; Guo T; Chan PY; Shaw G; Hines J; Stankiewicz E; Wang Y; Oliver RTD; Ahmad AS; Berney D; Shamash J; Lu YJ
Clin Cancer Res; 2017 Sep; 23(17):5112-5122. PubMed ID: 28615267
[No Abstract] [Full Text] [Related]
37. Circulating tumour cells-monitoring treatment response in prostate cancer.
Miyamoto DT; Sequist LV; Lee RJ
Nat Rev Clin Oncol; 2014 Jul; 11(7):401-12. PubMed ID: 24821215
[TBL] [Abstract][Full Text] [Related]
38. Evolution of the Liquid Biopsy in Metastatic Prostate Cancer.
Moreno JG; Gomella LG
Urology; 2019 Oct; 132():1-9. PubMed ID: 31207303
[TBL] [Abstract][Full Text] [Related]
39. Comparison of the PI3KCA pathway in circulating tumor cells and corresponding tumor tissue of patients with metastatic breast cancer.
Bredemeier M; Kasimir-Bauer S; Kolberg HC; Herold T; Synoracki S; Hauch S; Edimiris P; Bankfalvi A; Tewes M; Kimmig R; Aktas B
Mol Med Rep; 2017 May; 15(5):2957-2968. PubMed ID: 28358430
[TBL] [Abstract][Full Text] [Related]
40. Circulating Tumor Cells as a Biomarker of Survival and Response to Radium-223 Therapy: Experience in a Cohort of Patients With Metastatic Castration-Resistant Prostate Cancer.
Carles J; Castellano D; Méndez-Vidal MJ; Mellado B; Saez MI; González Del Alba A; Perez-Gracia JL; Jimenez J; Suárez C; Sepúlveda JM; Manneh R; Porras I; López C; Morales-Barrera R; Arranz JÁ
Clin Genitourin Cancer; 2018 Dec; 16(6):e1133-e1139. PubMed ID: 30104161
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]